YEAR-END REPORT JANUARY-DECEMBER 2013


Summary: full-year 2013

  · Net sales increased by 47% to SEK 8,912k (6,080k).

  · Operating loss improved by SEK 4,196k to SEK 15,985k (loss: 20,181k),
earnings per share improved to SEK -1.10 (-2.04).

  · Cash flow from operating activities was SEK -12,469k (-14,848k).

  · Genovis carried out two rights issues that raised about SEK 37.5 million
before issue expenses.

Summary: fourth quarter 2013

  · Net sales changed marginally compared with the fourth quarter of 2012.

  · Operating loss improved by SEK 3,106k to SEK 5,385k (loss: 8,491k), earnings
per share improved to SEK -0.34 (-0.70).

  · Cash flow from operating activities was SEK -1,502k (-3,889k).

  · Genovis launched two new products, FabULOUS and GlycINATOR for analysis and
characterization of antibody molecules.

  · Genovis was granted SEK 1 million in research support from VINNOVA (the
Swedish Agency for Innovation Systems) to explore a method for online process
control in conjunction with manufacturing of the biological drug, mAbCHECK.

  · Genovis carried out a rights issue in December that raised about SEK 23.7
million before issue expenses.
Comments from CEO Sarah Fredriksson

2013 is the first year that Genovis shows a positive earnings trend. I consider
this achievement to be one of the most important milestones in the Company's
development. Compared with 2012, sales rose 47 percent, while expenses increased
on an annualized basis to 13 percent, primarily due to expenses for
reorganization and continued investments in sales and marketing. Consequently,
financial performance for the full year remains unchanged, though it improved
over the first three quarters. I am not concerned about this variation over the
quarters; in fact, I believe we will continue to see this trend in the future.

We launched two new products in October. They were well-received by our
customers and sales took off immediately, which speaks well of our R & D
activities. During the fourth quarter, sales increased by about 70 percent in
Europe compared with the same period last year, at the same time that we
experienced a slowdown in the US market. We noted a cautious attitude in the US
during the autumn amid general concerns about the economic situation. The US
customers are at the forefront in the use of our products and they are heavily
involved in completely new applications. Consequently I do not believe that
interest is weakening, but rather the opposite and therefore believe this is a
temporary decline.  The reduced revenues in the US caused sales to remain
unchanged in the fourth quarter compared with the same quarter in 2012, despite
a strong increase in Europe. Expenses before depreciation and amortization rose
10 percent on a quarterly basis, with operating expenses increasing by 2.7
percent, while the rest are administrative costs of a nonrecurring nature.

We had three objectives for 2013: to launch two new product lines, to
substantially increase sales and for the protein products to become self
-sufficient. We achieved the first two objectives and the products in the
protein engineering portfolio generate sales that cover the costs of production,
administration and sales and marketing activities, while also generating a
contribution to research and development. While we did not quite achieve
objective number three during the year, we made great strides in the right
direction and will continue to do so in 2014. I believe we have every prospect
for success in this endeavor.

Sarah Fredriksson

CEO, Genovis AB
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00

Attachments

02174342.pdf